Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Accenture PLC (ACN) - free report >>
International Business Machines Corporation (IBM) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accenture PLC (ACN) - free report >>
International Business Machines Corporation (IBM) - free report >>
Image: Bigstock
Here's How IQVIA Will Benefit From Genomics England Allaince
IQVIA Holdings Inc. (IQV - Free Report) and Genomics England recently announced that they have partnered to build a real-world research platform, which integrates clinical and de-identified genomics data.
Genomics England is a company under the U.K. government’s Department of Health and Social Care. It was formed with the goal of sequencing 100,000 whole genomes from NHS patients and their families.
IQVIA Offering Healthcare Analytics Solution
Under the partnership, IQVIA will offer its E360 analytics technology to authorized users of Genomics England's database of de-identified genomic and phenotypic records. As a result, users will be able to develop custom clinical-genomic datasets and run analytics on genomics and observable traits.
The initiative focuses on patients with rare diseases as well as common cancer, and is expected to facilitate faster and more efficient drug research, stronger evidence to support treatment value, and greater access to personalized medicines.
The integrated genomic-clinical build of E360 will go online in 2019, after which the duo plans to serve academic and commercial researchers in genotype-phenotype association studies, comparative efficacy and safety trials, and burden-of-illness analytics. E360 is IQVIA’s extensible platform for delivering real-world Insights.
IQVIA’s Technology & Analytics Solutions Segment to Benefit
We believe that the recent collaboration will help boost IQVIA’s Technology & Analytics Solutions segment that delivers critical information, technology solutions and real-world insights and services to life science customers.
In the last reported quarter, the segment performed well with revenues totaling $1.01 billion, up 14.2% on a reported basis and 13.1% on a constant-currency basis.
With partnerships like this latest one, IQVIA is trying to keep itself ahead of its competitors like Verisk (VRSK - Free Report) , Accenture (ACN - Free Report) and International Business Machines Corporation (IBM - Free Report) .
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>